Cell No. : Cell Name
RCB1198 : TUHR4TKB
update : 2022/07/05
|
| Comment | Japanese renal carcinoma cells. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Kawai, Kouji & Ohno, Tadao
|
| Originator |
Liu Shu Qin
|
| Year of deposit |
1996
|
| Another name |
ToTe
|
| Animal |
human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
60 years
|
| Tissue |
kidney
|
| Classification |
cancer
|
| Year of origin |
1995
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_5957
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/10 days, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
51-57(50) : /52(5),53(2),54(9),55(21),56(10),57(2)
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
13
|
| User's Publication |
|
20629
Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.
Proc Natl Acad Sci U S A
2022
119(14):e2120403119
PubMed ID: 35357972
DOI: 10.1073/pnas.2120403119
|
|
3742
Çubuk C, Hidalgo MR, Amadoz A, Rian K, Salavert F, Pujana MA, Mateo F, Herranz C, Carbonell-Caballero J, Dopazo J.
Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models.
NPJ Syst Biol Appl
2019
5:7
PubMed ID: 30854222
DOI: 10.1038/s41540-019-0087-2
|
|
10839
Tsuchida A, Senda M, Ito A, Saito S, Kiso M, Ando T, Harduin-Lepers A, Matsuda A, Furukawa K, Furukawa K.
Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells.
Sci Rep
2018
8:7017
PubMed ID: 29728594
DOI: 10.1038/s41598-018-25521-6
|
|
3741
Saleeb RM, Farag M, Lichner Z, Brimo F3, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Mol Oncol
2018
12(10):1673-1688
PubMed ID: 29896907
DOI: 10.1002/1878-0261.12346
|
|
3740
Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA.
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Nat Commun. 2
2017
8:15165
PubMed ID: 28489074
DOI: 10.1038/ncomms15165
|
|
3745
Ning Z, Yongjing L, Yunzhen W, Zichuang Y, Qiang Z, Cheng W, Zhiqiang C, Yan X.
Optimization of cell lines as tumour models by integrating multi-omics data.
Brief Bioinform
2017
18(3):545
PubMed ID: 28013237
DOI: 10.1093/bib/bbw121
|
|
7606
Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M, Moriyama M.
Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma.
BMC Cancer
2011
11:523
PubMed ID: 22185343
DOI: 10.1186/1471-2407-11-523
|
|
8356
Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T.
NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.
Br. J. Cancer
2010
102:873-82
PubMed ID: 20160729
DOI: 10.1038/sj.bjc.6605574
|
|
6387
Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K.
DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma.
Clin Cancer Res
2010
16(10):2751-9
PubMed ID: 20460473
DOI: 10.1158/1078-0432.CCR-09-3338
|
|
3396
Yamada, Daisuke, Kikuchi, Shinji, Williams, Yuko N, Sakurai-Yageta, Mika, Masuda, Mari, Maruyama, Tomoko, Tomita, Kyoichi, Gutmann, David H, Kakizoe, Tadao, Kitamura, Tadaichi, Kanai, Yae, Murakami, Yoshinori
Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.
Int J Cancer
2006
118:916-23
PubMed ID: 16152585
DOI: 10.1002/ijc.21450
|
|
5012
Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.
Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
Hum Mol Genet
2006
15(6):821-30
PubMed ID: 16439445
DOI: 10.1093/hmg/ddl001
|
|
6450
Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.
Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Oncol Rep
2004
12(4):805-10
PubMed ID: 15375503
|
|
1958
Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.
Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads
Cytotechnology
1998
26(1):13-21
PubMed ID: 22359002
DOI: 10.1023/A:1007924430570
|
Back
Top
CELL BANK Website